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Joseph Miller6, Jeffrey Zhang7, Kenneth Stauderman8, Sudarshan Hebbar8* and Peter C. Hou9†

Abstract
Background: Calcium release-activated calcium (CRAC) channel inhibitors block proinflammatory cytokine release,
preserve endothelial integrity and may effectively treat patients with severe COVID-19 pneumonia.
Methods: CARDEA was a phase 2, randomized, double-blind, placebo-controlled trial evaluating the addition of
Auxora, a CRAC channel inhibitor, to corticosteroids and standard of care in adults with severe COVID-19 pneumonia.
Eligible patients were adults with ≥ 1 symptom consistent with COVID-19 infection, a diagnosis of COVID-19 con‑
firmed by laboratory testing using polymerase chain reaction or other assay, and pneumonia documented by chest
imaging. Patients were also required to be receiving oxygen therapy using either a high flow or low flow nasal can‑
nula at the time of enrolment and have at the time of enrollment a baseline imputed P
 aO2/FiO2 ratio > 75 and ≤ 300.
The PaO2/FiO2 was imputed from a SpO2/FiO2 determine by pulse oximetry using a non-linear equation. Patients
could not be receiving either non-invasive or invasive mechanical ventilation at the time of enrolment. The primary
endpoint was time to recovery through Day 60, with secondary endpoints of all-cause mortality at Day 60 and Day
30. Due to declining rates of COVID-19 hospitalizations and utilization of standard of care medications prohibited by
regulatory guidance, the trial was stopped early.
Results: The pre-specified efficacy set consisted of the 261 patients with a baseline imputed P
 aO2/FiO2≤ 200 with
130 and 131 in the Auxora and placebo groups, respectively. Time to recovery was 7 vs. 10 days (P = 0.0979) for
patients who received Auxora vs. placebo, respectively. The all-cause mortality rate at Day 60 was 13.8% with Auxora
vs. 20.6% with placebo (P = 0.1449); Day 30 all-cause mortality was 7.7% and 17.6%, respectively (P = 0.0165). Similar
trends were noted in all randomized patients, patients on high flow nasal cannula at baseline or those with a baseline
imputed PaO2/FiO2 ≤ 100. Serious adverse events (SAEs) were less frequent in patients treated with Auxora vs. placebo
and occurred in 34 patients (24.1%) receiving Auxora and 49 (35.0%) receiving placebo (P = 0.0616). The most com‑
mon SAEs were respiratory failure, acute respiratory distress syndrome, and pneumonia.
Conclusions: Auxora was safe and well tolerated with strong signals in both time to recovery and all-cause mortal‑
ity through Day 60 in patients with severe COVID-19 pneumonia. Further studies of Auxora in patients with severe
COVID-19 pneumonia are warranted.
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Trial registration NCT04345614.

Introduction
The COVID-19 pandemic has caused nearly 5.5 million deaths worldwide and more than 820,000 deaths
in the US [1]. Although most cases are asymptomatic
or mild, up to 20% of patients progress to develop
severe pneumonia, requiring hospitalization and
intensive care, with mortality rates near 30% in highrisk groups [2–6]. In the US alone, more than 2.6
million patients with COVID-19 have been hospitalized [7]. To address this global health crisis, antiviral
treatments have been utilized to decrease the time to
recovery and immunomodulatory therapies have been
administered as they have demonstrated some efficacy
at reducing mortality among hospitalized patients but
additional novel therapeutics are urgently needed
[8–10].
In patients with severe COVID-19 pneumonia,
broad dysregulated immune responses have been
identified with patients showing elevations in a range
of proinflammatory cytokines [11–18]. These pathophysiologic events suggest that treatments with
broad-based immunomodulatory effects may be more
effective in treating COVID-19 pneumonia than those
targeting specific immune pathways to prevent disease
progression [11–19]. One such potential treatment is
Auxora, a calcium release-activated calcium (CRAC)
channel inhibitor. CRAC channel inhibition by the
active ingredient in Auxora, CM4620, has been shown
to block the release of multiple pro-inflammatory
cytokines, including interleukin (IL)-6 [20]. Further,
in a Phase 2 open-label study in patients with acute
pancreatitis with accompanying systemic inflammatory response syndrome (SIRS) and hypoxemia, it was
noted that Auxora rapidly lowered IL-6 levels in those
patients presenting with levels > 150 pg/mL [21]. The
reduction in IL-6 supported the start of an open-label
study of Auxora in patients with severe COVID-19
pneumonia in the spring of 2020. The initial openlabel trial showed Auxora was safe and reduced the
occurrence of a composite of death and need for invasive mechanical ventilation [22]. Given these initial
results, a randomized, placebo-controlled trial was
initiated to test the hypothesis that the inhibition
of CRAC channels by Auxora may effectively treat
patients with severe COVID-19 pneumonia.

Methods
Trial design and oversight

CARDEA was a phase 2, randomized, double-blind, placebo-controlled trial that tested the addition of Auxora
to corticosteroids and standard of care in patients with
severe COVID-19 pneumonia (ClinicalTrials.gov identifier, NCT04345614). The study of Auxora in patients with
severe COVID-19 pneumonia was initially conducted as
an open-label study that started enrollment on April 8,
2020. The FDA provided guidance on May 12, 2020, to
limit further enrollment under the open-label design and
transition to a randomized, double-blind, placebo-controlled trial. As such, the open-label study was terminated
on May 13, 2020 and the results were published [22].
CARDEA was initially designed to enroll 400 patients
with two specified groups that were to be stratified
equally across the treatment arms: 80 patients with
a baseline imputed P
 aO2/FiO2 ratio of > 200 and 320
patients with a baseline imputed 
PaO2/FiO2 ratio of
≤ 200. The P
 aO2/FiO2 was imputed from a S
 pO2/FiO2
using a non-linear equation. The S
pO2 was obtained
using pulse oximetry. The F
 iO2 was read from the controlled oxygen source in patients requiring high flow
nasal cannula. For patients on an uncontrolled oxygen
source, a conversion table was provided to all sites to estimate the F
 iO2 based on the method of oxygen delivery
and oxygen flow rate [23]. The baseline imputed PaO2/
FiO2 was the worst value in the 24 h prior to screening.
It had been noted in the open-label study that patients
with a baseline imputed 
PaO2/FiO2 > 200 had neither
required invasive mechanical ventilation nor died so
their enrollment in CARDEA was to confirm this observation [22]. After the first 23 patients with a baseline
imputed PaO2/FiO2 > 200 were randomized, a blinded
analysis confirmed this observation. As a result, further
enrollment of this patient subgroup was halted following
the first IDMC review to avoid impacting efficacy signals
from the study. From that point forward, only patients
with a baseline imputed 
PaO2/FiO2 ≤ 200 were randomized into the study with the enrollment goal of 320
patients in this group being unchanged. The study was
terminated, however, after 261 patients with a baseline
imputed PaO2/FiO2 ratio ≤ 200 were randomized based
on declining rates of US COVID-19 hospitalizations in
the spring of 2021 and the more frequent use of tocilizumab in CARDEA candidate patients at many trial sites
following recommendations by the National Institutes
of Health’s COVID-19 Treatment Guidelines Panel [24].
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The use of tocilizumab in combination with Auxora had
been prohibited by regulatory guidance.
In CARDEA, patients were randomized 1:1 to Auxora
plus standard of care or placebo plus standard of care.
Participants, investigators, study teams, and the sponsor
were all blinded to study drug assignment. Randomization was stratified by the baseline imputed P
 aO2/FiO2
ratio of > 200 vs ≤ 200 through a central, concealed, webbased, automated system. An independent statistician
created the randomization schedule with stratified block
randomization method using SAS proc plan procedure.
Within each stratum, the treatment codes were assigned
at a 1:1 ratio of Auxora and placebo with the block size
of 4.
Auxora was administered by a 4-h IV infusion at
2.0 mg/kg (1.25 mL/kg) at 0-h and 1.6 mg/kg (1 mL/kg) at
24 and 48 h. Placebo was a matching formulation without
the active pharmaceutical ingredient and was also dosed
as a 4-h IV infusion at 1.25 mL/kg at 0-h and 1 mL/kg at
24 and 48 h. Patients were assessed for recovery and mortality using an ordinal scale in a standardized manner as
described in the electronic case report form. The initial
assessments occurred immediately before each infusion.
Seventy-two hours after the start of the first infusion,
patient assessment occurred every 24 h (± 4 h) until
240 h and then continued every 48 h until Day 30 or discharge. Patients discharged before Day 25 were contacted
at Day 30 (± 5 days). All patients were again assessed Day
60 (± 5 days); patients who remained in the hospital after
Day 30 were assessed by review of hospital records and
those who had been discharged were contacted by telephone. Public information (e.g., death reports, governmental information) was used by sites to ascertain Day
60 mortality status in patients who refused direct contact
after discharge or had withdrawn from the trial.
All patients were required to receive dexamethasone or
equivalent dose of another corticosteroid as well as pharmacological prophylaxis against development of venous
thromboembolic disease. Remdesivir use was recommended for all patients, and convalescent plasma administration was allowed according to local standard of care.
Other immunomodulators for the treatment of COVID19 pneumonia, including tocilizumab and JAK inhibitors,
were prohibited due to regulatory guidance.
An institutional review board at each site approved
the trial protocol. Informed consent was obtained from
the patient or the patient’s legally authorized representative if the patient was unable to provide consent. The
trial was conducted in accordance with Good Clinical
Practice guidelines and the principles of the Declaration
of Helsinki, and was sponsored by CalciMedica, Inc (La
Jolla, CA). An independent data monitoring committee
(IDMC) provided trial oversight. Operational support
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was provided by Bionical-Emas (Paulsboro, NJ) and
Princeton Pharmatech (San Francisco, CA) performed
the statistical analyses. All authors vouch for the accuracy and completeness of the data and for the fidelity of
the trial adherence to the protocol.
The IDMC first reviewed unblinded safety data once 57
patients were randomized, then again after 70 patients
with a baseline imputed P
aO2/FiO2 ≤ 200 completed
60 days of the trial, and finally after randomization of
209 patients with a baseline imputed P
 aO2/FiO2 ≤ 200.
The IDMC also performed an interim sample size re-estimation based on the recovery rate ratio after 70 patients
with a baseline imputed PaO2/FiO2 ≤ 200 reached Day
60.
Patient population

Eligible patients were adults with ≥ 1 symptom consistent with COVID-19 infection, a diagnosis of COVID-19
confirmed by laboratory testing using polymerase chain
reaction or other assay, and pneumonia documented by
chest imaging. Patients were also required to be receiving oxygen therapy using either a high flow (HFNC) or
low flow nasal cannula and have at the time of enrolment a baseline imputed PaO2/FiO2 ratio > 75 and ≤ 300.
Patients could not be receiving either non-invasive or
invasive mechanical ventilation at the time of enrolment.
Full inclusion and exclusion criteria are available in the
Additional file 1: Appendix.
Outcomes

The primary endpoint was time to recovery through Day
60, defined as meeting the criteria for category 6 (Hospitalized, not requiring supplemental oxygen or ongoing medical care), category 7 (Discharged, requiring
supplemental oxygen), or category 8 (Discharged, not
requiring supplemental oxygen) using an 8-point ordinal
scale. The key secondary endpoint of all-cause mortality
at Day 60 was requested by regulatory guidance. Additional secondary endpoints evaluated in the efficacy set
included all-cause mortality at Day 30, the proportion
of patients requiring invasive mechanical ventilation or
death through Day 60, the proportion of patients requiring invasive mechanical ventilation through Day 60, and
differences in outcomes measured by the 8-point ordinal scale through Day 60. Safety endpoints included the
occurrence and severity of treatment-emergent adverse
events (TEAEs) and serious AEs (SAEs).
The primary and key secondary endpoints were also
evaluated in pre-specified subgroups of patients who
required oxygen therapy via either HFNC or low flow
nasal cannula at baseline or patients having a baseline
imputed PaO2/FiO2 ≤ 100 or 101–200 at baseline, and
in all randomized patients. The safety endpoints were
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evaluated in all patients who received study drug, including those with a baseline imputed PaO2/FiO2 > 200.
Statistical analysis

The efficacy set was pre-specified, consisting of those
patients with a baseline imputed P
aO2/FiO2 ≤ 200. A
two-group log-rank test with a 0.05 two-sided significance level would have 90% power to detect a difference
in the recovery rate ratio of approximately 1.49 in the 320
patients with a baseline imputed P
 aO2/FiO2 ≤ 200 who
were randomized 1:1 to Auxora or placebo. The Sponsor elected to not change the sample size after the IDMC
performed the sample size re-estimation. All supplemental analyses of the primary and first secondary endpoints
were also performed in a set of all randomized patients.
Time to recovery through Day 60 in the efficacy set
was compared between the Auxora and placebo groups
using log-rank test stratified by baseline imputed PaO2/
FiO2 ≤ 100 vs. 101–200 and displayed using a Kaplan–
Meier estimate. Patients were censored at the last ordinal
scale assessment if no recovery event was observed during the study and if they had recovered, been discharged,
but Day 60 recovery status was not obtained.
All-cause mortality at Day 60 in the efficacy set was
compared between the Auxora and placebo groups using
a Cochran-Mantel- Haenszel test stratified by the baseline imputed P
 aO2/FiO2 ≤ 100 vs. 101–200. In addition,
a sensitivity analysis was performed that estimated the
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60-day death rate with hypothesis testing based on the
Kaplan–Meier estimates and standard errors estimated
by Greenwood formula using the log–log transformation
of the survival function stratified by the baseline imputed
PaO2/FiO2 of ≤ 100 vs. 101–200.
To protect the trial level type 1 error rate at α = 5% (two
sided) between the primary endpoint analysis and the key
secondary endpoint analysis, the Benjamini and Hochberg testing strategy was used as test statistics of time to
recovery and all-cause mortality at Day 60 were positively
correlated.
Role of funding source

The funder of the study had primary responsibility for
the study design, protocol development, study monitoring, data management and interpretation, and statistical
analyses. The funder also contributed to the drafting of
the manuscript and decision to submit.

Results
Patients

Patient enrollment occurred from September 8, 2020 to
May 24, 2021. A total of 284 patients were randomized
across 17 US centers, 143 to Auxora and 141 to placebo
(Fig. 1), and 281 patients received at least one dose of
study drug. The efficacy set consisted of 261 patients with
a baseline imputed P
 aO2/FiO2 ≤ 200 with 130 in Auxora
and 131 in placebo groups (Fig. 1). One patient was lost

Fig. 1 Patient Enrolment and Randomization. *Reasons for screen failure included PaO2/FiO2 ≤ 75 (n = 3), at least 1 of the following signs at
Screening or noted in the 24 h before Screening: SpO2 < 92% on room air; PaO2/FiO2 = 300 when receiving low flow supplemental oxygen (n = 3),
do not intubate order (n = 2), prohibited medication (n = 1), history of organ or hematologic transplant, HIV, Active hepatitis B, or hepatitis C
infection (n = 1); †One patient in the Auxora arm and one patient in the placebo arm who had a baseline imputed P
 aO2/FiO2 ≤ 200 at baseline did
not receive any doses
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to follow up. In total, Day 60 mortality status was documented in 283 and Day 60 recovery status as determined
by the ordinal scale was documented in 275 of the 284
patients randomized in the study.
All patients (100%) in the efficacy set received corticosteroids (85.8%, dexamethasone), 75.9% received
remdesivir, and 99.6% received anticoagulation (93.1%,
enoxaparin [dosed for venous thromboembolic disease
prophylaxis]; Additional file 1: Table S1). Tocilizumab,
while a prohibited medication, was administered to 8
patients after randomization, and 6 were determined to
have received placebo after unblinding.
Baseline characteristics were well balanced between the
Auxora and placebo groups in the efficacy set (Table 1)
and among all randomized patients (Additional file 1:
Table S2). The mean age across both treatment arms
was 60 years; 67.4% were male, and 39.5% were Hispanic
or Latino; there was a higher percentage of men in the
placebo group. The mean time from symptom onset to
randomization was 12 days, and 62.5% required oxygen
therapy via HFNC at baseline; 44.8% of patients had a
baseline imputed PaO2/FiO2 ≤ 100 at baseline.
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Time to recovery

The median time to recovery was 7 days (95% CI, 6.0, 9.0)
and 10 days (95% CI, 7.0, 14.0; P = 0.0979) for patients in
the Auxora and placebo groups, respectively (Table 2). In
the subgroups of patients who required oxygen therapy
via HFNC at baseline or had a baseline imputed PaO2/
FiO2 ≤ 100 at baseline, patients in the Auxora group had
a faster time to recovery, compared to the placebo group
(Table 3). Similar results were noted when all randomized
patients were analyzed (Additional file 1: Table S3).
All‑cause mortality

The all-cause mortality rate at Day 60 was 13.8% (n = 18)
in patients treated with Auxora and 20.6% (n = 27)
with placebo (difference −6.75; 95% CI −15.75, 2.24;
P = 0.1449; Table 2; Additional file 1: Figure S1). The allcause mortality rate at Day 30 was 7.7% in patients treated
with Auxora and 17.6% with placebo (difference −9.86;
95% CI −17.80, −1.83; P = 0.0165; Table 2; Additional
file 1: Figure S1). Lower mortality rates at Day 60 were
observed in subgroups of patients using HFNC at baseline or those with a baseline imputed PaO2/FiO2 ≤ 100
at baseline (Table 3; Additional file 1: Figures S2, S3) and

Table 1 Baseline characteristics in patients with a baseline imputed PaO2/FiO2 ≤ 200
Placebo
(n = 131)

Auxora
(n = 130)

Total
(N = 261)

92 (70.2%)

84 (64.6%)

176 (67.4%)

White, n (%)

98 (74.8%)

85 (65.4%)

183 (70.1%)

Black, n (%)

12 (9.2%)

19 (14.6%)

31 (11.9%)

Asian

5 (3.8%)

9 (6.9%)

14 (5.4%)

Other/multiple*

16 (12.2%)

16 (12.3%)

32 (12.3%)

Hispanic, n (%)

58 (44.3%)

45 (34.6%)

103 (39.5%)

Mean age, years (SD)

60.4 (12.3)

59.4 (12.1)

59.9 (12.2)

65+ years of age, n (%)

47 (35.9%)

45 (34.6%)

92 (35.2%)

Mean BMI, kg/m2 (SD)

32.0 (7.0)

32.8 (8.8)

32.4 (8.0)

Mean time from symptom onset, days (SD)

12.0 (5.9)

12.2 (5.8)

12.1 (5.8)

Median time from hospitalization to randomization, days

3.0

3.0

3.0

HFNC use, n (%)

82 (62.6%)

81 (62.3%)

163 (62.5%)

Mean baseline imputed PaO2/FiO2 value† (SD)

105.1 (32.8)

109.7 (36.8)

107.4 (34.8)

Male, n (%)
Race

Baseline imputed PaO2/FiO2 ≤ 100, n (%)

58 (44.3%)

59 (45.4%)

117 (44.8%)

Baseline imputed PaO2/FiO2 101–200, n (%)

73 (55.7%)

71 (54.6%)

144 (55.2%)

Mean CRP, mg/L (SD)

92.5 (67.6)

93.1 (71.2)

92.8 (69.2)

Mean ferritin, ng/mL (SD)

1050 (869)

1027 (907)

1039 (886)

Hypertension, n (%)

80 (61.1%)

84 (64.6%)

164 (62.8%)

Diabetes, n (%)

57 (43.5%)

52 (40.0%)

109 (41.8%)

Hyperlipidemia, n (%)

51 (38.9%)

50 (38.5%)

101 (38.7%)

Former Smoker, n (%)

34 (26.0%)

39 (30.0%)

73 (28.0%)

*Other include Native Hawaiian or other Pacific Islander. One participant in the Auxora group was missing race at baseline
†

Worst value in the 24 h prior to Screening. Patients with a baseline imputed P
 aO2/FiO2 > 200 were excluded from the efficacy set analysis

BMI body mass index, CRP C-reactive protein, HFNC high flow nasal cannula, SD standard deviation
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Table 2 Primary and secondary endpoints in patients with a baseline imputed P
 aO2/FiO2 ≤ 200
Placebo
(n = 131)

Auxora
(n = 130)

Difference
(95% CI)

P value

10.0 (7.0, 14.0)

7.0 (6.0, 9.0)

All-cause mortality at Day 60, n (%)

27 (20.6%)

18 (13.8%)

− 6.75
(− 15.75, 2.24)

0.1449

All-cause mortality at Day 30, n (%)

23 (17.6%)

10 (7.7%)

0.0165

Invasive Mechanical Ventilation, Proportion of Patients Day
60 (95% CI)

0.28
(0.21, 0.37)

0.19
(0.13, 0.28)

− 9.86
(− 17.80, − 1.93)

Invasive Mechanical ventilation or death, proportion of
patients Day 60 (95% CI)

0.31
(0.24, 0.39)

0.23
(0.17, 0.31)

Primary endpoint
Median time to recovery, days (95% CI)

0.0979

Secondary endpoints

0.1882
0.2994

Definition of Recovery by Ordinal Scale: 6 Hospitalized, not requiring supplemental oxygen or ongoing medical care; 7 Discharged, requiring supplemental oxygen; 8
Discharged, not requiring supplemental oxygen. Analysis of time to recovery through Day 60 in the efficacy set used log-rank test stratified by the baseline imputed
PaO2/FiO2 ≤ 100 and 101–200; Analysis of all-cause mortality in the efficacy set used Cochran-Mantel–Haenszel test stratified by the baseline imputed P
 aO2/FiO2 ≤ 100
and 101–200. Patients with a baseline imputed PaO2/FiO2 > 200 were excluded from the efficacy set analysis

Table 3 Time to recovery and all-cause mortality by oxygen delivery mode and baseline imputed P
 aO2/FiO2 at baseline
Oxygen delivery at baseline
HFNC
Placebo
(n = 82)

Auxora
(n = 81)

Difference
(95% CI)

P value

Median time to recovery, days (95%
CI)

17.0 (8.0, 30.0)

9.0 (7.0, 13.0)

All-Cause Mortality at Day 60, n (%)

21 (25.6%)

13 (16.0%)

−9.36
(−21.79, 3.07)

0.1436

Placebo
(n = 49)

Auxora
(n = 49)

Difference
(95% CI)

P value

Median time to recovery, days (95%
CI)

7.0 (5.0, 9.0)

5.0 (4.0, 6.0)

All-Cause Mortality at Day 60, n (%)

6 (12.2%)

5 (10.2%)

−2.04
(−14.53, 10.45)

0.7490

Placebo
(n = 58)

Auxora
(n = 59)

Difference
(95%CI)

P value

Median time to recovery, days (95%
CI)

23.0 (11.0, 70.0)

11.5 (8.0, 23.0)

All-Cause Mortality at Day 60, n (%)

17 (29.3%)

12 (20.3%)

−8.62
(−24.30, 7.06)

0.2837

Placebo
(n = 73)

Auxora
(n = 71)

Difference
(95% CI)

P Value

Median time to recovery, days (95%
CI)

7.0 (5.0, 8.0)

6.0 (5.0, 7.0)

All-Cause Mortality at Day 60, n (%)

10 (13.7%)

6 (8.5%)

0.1079

Low flow oxygen

0.4195

Baseline imputed PaO2/FiO2 at baseline
≤ 100

0.1040

101–200

0.4156
−5.25
(−15.45, 4.95)

0.3164

Definition of Recovery by Ordinal Scale: 6 Hospitalized, not requiring supplemental oxygen or ongoing medical care; 7 Discharged, requiring supplemental oxygen;
8 Discharged, not requiring supplemental oxygen. Kaplan–Meier estimate of Days to Recovery with P value based on log-rank test without stratification. Unstratified
analysis of mortality using Chi-squared test. HFNC, high flow nasal cannula. Patients with a baseline imputed P
 aO2/FiO2 > 200 were excluded from the efficacy set
analysis
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Fig. 2 Proportion of Patients with a Baseline Imputed PaO2/FiO2 ≤ 200 in Each Ordinal Scale Category Over Time. A higher proportion of patients
receiving Auxora were discharged, and a lower proportion progressed to invasive mechanical ventilation, ECMO, and death at Day 60 (Odds Ratio,
0.647; 95% CI 0.405, 1.031; P = 0.0672) and Day 30 (Odds Ratio, 0.617; 95% CI 0.387, 0.983; P = 0.0423). Efficacy outcome measured with the 8-point
ordinal scale included recovery rate defined as the first day the patient satisfied criteria 6, 7, or 8 and change in the 8-point ordinal scale over time.
The proportions are compared between the two treatment groups using a proportional odds model with a fixed factor of treatment groups. ECMO,
Extracorporeal membrane oxygenation

in all randomized patients (Additional file 1: Table S3).
Additional pre-specified subgroup analyses for mortality
are noted in Additional file 1: Figure S4.
Additional secondary endpoints demonstrated potential benefits with Auxora vs. placebo (Table 2), including
a higher proportion of patients receiving Auxora being
discharged, and a lower proportion progressing to invasive mechanical ventilation, extracorporeal membrane
oxygenation, and death at Day 60 (Odds Ratio, 0.647;
95% CI 0.405, 1.031; P = 0.0672) and Day 30 (Odds Ratio,
0.617; 95% CI 0.387, 0.983; P = 0.0423; Fig. 2).
Safety outcomes

In total, 34 patients (24.1%) in the Auxora and 49 (35.0%)
in the placebo groups experienced SAEs (P = 0.0616).
The most common SAEs were respiratory failure, acute
respiratory distress syndrome (ARDS), and pneumonia (Table 4). Discontinuation due to TEAEs occurred
in 3 patients in the Auxora and 5 patients in the placebo
groups. The most common TEAEs were respiratory failure, increasing triglycerides, hyperglycemia, and acute
kidney injury.

Discussion
Auxora was initially studied in patients with acute pancreatitis and accompanying SIRS and hypoxemia [21].
In this study, it was noted that Auxora decreased IL-6
levels in patients presenting with IL-6 ≥ 150 pg/mL,
including 2 patients with values > 1000 pg/mL [21]. This
result was consistent with in vitro effects of Auxora on
cytokine release in human lymphocytes [20]. Based
on these findings and the idea that COVID-19 pneumonia involved dysregulated immune and endothelial responses, it was hypothesized that Auxora may
be effective in treating patients with severe COVID19 pneumonia. Mortality and biomarker results from
an initial, open-label study of Auxora in patients with
severe COVID-19 pneumonia encouraged the transition to the current randomized, double-blind, placebocontrolled CARDEA trial [22, 25].
Results from the CARDEA trial suggest a potential
therapeutic benefit of Auxora in addition to corticosteroids and standard of care in patients with severe
COVID-19 pneumonia [22]. While not statistically significant, more patients with a baseline imputed P
 aO2/
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Table 4 Safety outcomes in all patients receiving at least one
dose of study drug
Placebo (n = 140) Auxora (n = 141)
Discontinuation due to AEs, n
(%)

5 (3.6%)

3 (2.1%)

Respiratory failure

26 (18.6%)

22 (15.6%)

ARDS

11 (7.9%)

7 (5.0%)

Pneumonia

7 (5.0%)

6 (4.3%)

Cardiac arrest

6 (4.3%)

6 (4.3%)

Septic shock

8 (5.7%)

2 (1.4%)

Serious adverse events ≥ 4%, n (%)

Most common treatment-emergent adverse events ≥ 4%, n (%)
Respiratory failure

26 (18.6%)

22 (15.6%)

Blood triglycerides increased

5 (3.6%)

16 (11.3%)

Hypertriglyceridemia

4 (2.9%)

2 (1.4%)

Hyperglycemia

11 (7.9%)

11 (7.8%)

Acute kidney injury

16 (11.4%)

10 (7.1%)

Increased transaminases

5 (3.6%)

8 (5.7%)

Liver function test increased

1 (0.7%)

5 (3.5%)

ARDS

11 (7.9%)

7 (5.0%)

DVT

7 (5.0%)

7 (5.0%)

Pneumonia

7 (5.0%)

7 (5.0%)

Pneumothorax

6 (4.3%)

7 (5.0%)

Pneumomediastinum

2 (1.4%)

6 (4.3%)

Hypoxia

7 (5.0%)

6 (4.3%)

Cardiac arrest

6 (4.3%)

6 (4.3%)

Hyperkalemia

6 (4.3%)

4 (2.8%)

Anemia

9 (6.4%)

3 (2.1%)

Septic Shock

13 (9.3%)

2 (1.4%)

AEs adverse events, ARDS acute respiratory distress syndrome, DVT deep vein
thrombosis

FiO2 ≤ 200 who received Auxora met the primary endpoint of time to recovery through Day 60. In addition,
patients who received Auxora had a lower all-cause
mortality rate at both Days 60 and 30. Patients, who
required oxygen therapy via HFNC at baseline or had
a baseline imputed P
 aO2/FiO2 ≤ 100 at baseline may
have benefited the most from the addition of Auxora to
corticosteroids and standard of care. There were similar
trends when all randomized patients were analyzed.
Auxora was generally safe and well tolerated. Of note,
reported AEs for elevated blood triglyceride levels and
liver function tests were increased in patients in the
Auxora arm when compared with placebo. None of the
episodes of hypertriglyceridemia in the Auxora group
were reported as being severe. One case of elevated
transaminases in the Auxora group was considered
severe and occurred in a patient also receiving remdesivir, simvastatin, and ezetimibe. The increased levels
resolved with discontinuation of Auxora.

CRAC channels have been shown to play important roles in several cell types and pathways linked to
COVID-19 pneumonia [26]. These channels are mainly
composed of the plasma membrane C
 a2+ conductance
protein Orai1 and the endoplasmic reticulum (ER)
Ca2+ sensing protein stromal interaction molecule 1
(STIM1) [26]. When 
Ca2+ is released from the ER,
the drop in ER luminal C
 a2+ concentration is sensed
by STIM1, which undergoes a conformational change
resulting in Orai1 activation and C
 a2+ entry into the
cell [26]. Blockade of CRAC channels with the selective Orai1 CRAC channel inhibitor Auxora abrogates
the release of multiple proinflammatory cytokines
from human lymphocytes, including IL-6, IL-17, and
IFNγ that have been implicated in COVID-19 alveolitis
(Fig. 3) [16, 27]. Since the Ca2+ entering through CRAC
channels in T cells primarily activates the calcineurin/
nuclear factor of activated T-cells signal transduction
pathway, CRAC channel inhibitors may act cooperatively with standard of care anti-inflammatory drugs
such as dexamethasone that work through the NF-kB
signal transduction pathway [27–29]. Inhibitors of IL-6,
such as tocilizumab, and JAK inhibitors, such as baricitinib, may also work in concert with CRAC channel
inhibition, although the safety of these combinations
is yet to be studied. Importantly, in addition to effects
on the immune system, pathophysiologically-activated
CRAC channels have been associated with pulmonary
endothelial cell dysfunction and plasma extravasation
in animal models of acute lung injury [30, 31]. CRAC
channel inhibition in these models protects endothelial
cells and reduces inflammation and plasma extravasation [31, 32]. Finally, CRAC channels have been shown
to regulate cytokine release from alveolar macrophages,
which have been implicated in COVID-19 pneumonia
[16, 33]. Thus, inhibition of CRAC channels by Auxora
may provide the kind of broad-based approach likely to
be effective in treating patients with severe COVID-19
pneumonia (Fig. 3).
Limitations in this study include the early termination of the study that caused the study to be underpowered, as the total number of study patients was
reduced from the originally planned 400 to 284. In
addition, the studied population is a small percentage of the total number of patients hospitalized with
COVID-19, as patients with a baseline imputed PaO2/
FiO2 > 300, with a baseline imputed PaO2/FiO2 ≤ 75,
and patients already receiving noninvasive or invasive
mechanical ventilation were not enrolled in the study.
Therefore, these results may not extend to a broader
population with COVID-19. In addition, there are
concerns about the validity of imputing the PaO2/FiO2
ratio using the non-linear formula in patients with
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Fig. 3 Proximal Role of CRAC Channel-mediated IFN-γ in COVID-19 Pneumonia. Tissue resident alveolar macrophages respond to SARS-CoV-2
infection in the lung by producing T-cell chemoattractants. Arriving T cells produce IFNγ, leading to further alveolar macrophage activation and
recruitment of monocyte-derived alveolar macrophages [15, 16]. The feedback loop leads to a rapid increase in proinflammatory cytokines,
diffuse alveolar injury, severe endothelialitis, ARDS, and multiorgan dysfunction and failure [14, 17, 18]. Auxora abrogates the release of multiple
proinflammatory cytokines from human lymphocytes, including IL-6, IL-17, and IFNγ that are implicated in COVID-19 alveolitis [16, 27]. Adapted
from Grant RA, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847);635–641. IL, interleukin;
IFNγ, interferon-gamma; ROS, reactive oxygen species

COVID-19 as it can influence the definition of severe
pneumonia. Finally, while this study should be considered as proof-of-concept for the use of Auxora in the
treatment of patients with severe COVID-19 pneumonia, the added benefit and risk of Auxora used in
combination with currently accepted standard of care
medications is unknown and will require testing in
future clinical trials. In the initial open label study, the
sponsor obtained regulatory approval to allow investigators to administer corticosteroids to patients with
progressing COVID-19 pneumonia [22]. Other immunomodulatory medications were prohibited. CARDEA
initiated enrollment after steroids had become
accepted as standard of care for patients hospitalized
with COVID-19 pneumonia [24]. While CARDEA was
underway, baricitinib plus remdesivir was shown to be
superior to remdesivir alone in reducing recovery time
in patients on high flow ventilation and non-invasive
ventilation [10]. Tocilizumab and sarilumab, medications prohibited in CARDEA by regulatory guidance,
were also shown to improve outcomes, including mortality, in critically ill patients with COVID-19 receiving organ support in the intensive care unit [34].

Conclusions
Mechanistically, CRAC-channel inhibitors, such as
Auxora, may have therapeutic efficacy in both hastening recovery and reducing mortality in severe
COVID-19 pneumonia, and as such, warrant continued

clinical development. Results from this phase 2 trial demonstrated that Auxora was safe and well tolerated with
strong signals in both time to recovery and all-cause
mortality. These results provide support for a follow-up
trial of Auxora in patients with severe COVID-19 pneumonia to confirm benefit when used in combination with
current standard of care.
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